MIM
NEOS

MetLife Investment Management’s Neos Therapeutics, Inc NEOS Stock Holding History

MetLife Investment Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,089
Closed -$134K – 2227
2017
Q4 		$134K Buy
+13,089
New +$126K ﹤0.01% 2127

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's NEOS Position: Q1 2018 in Review

MetLife Investment Management sold out of Neos Therapeutics, Inc (NEOS) in Q1 2018, closing a stake of 13,089 shares — an estimated $134K sold.

MetLife Investment Management first reported a position in NEOS in Q4 2017 and held it in 1 quarter. The position peaked at $134K in Q4 2017. 77 funds tracked by Wall St. Rank hold NEOS as of Q1 2018.

  • MetLife Investment Management reported no remaining Neos Therapeutics, Inc position as of Q1 2018 after selling out during the quarter.
  • MetLife Investment Management sold 13,089 Neos Therapeutics, Inc shares in Q1 2018, an estimated $134K.
  • MetLife Investment Management first reported a position in Neos Therapeutics, Inc in Q4 2017 and held it in 1 quarter.
  • MetLife Investment Management's Neos Therapeutics, Inc position peaked at $134K in Q4 2017.
  • 77 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2018.

Based on MetLife Investment Management's 13F filing for Q1 2018, filed 15 May 2018.